Mylan (MYL) Sued by Shareholder Over EpiPen Payments
- Nasdaq, S&P tumble as Netflix, chip stocks drag; AmEx boosts Dow
- Sony/Apollo bid for Paramount could be worth as much as $29 billion - Source
- Netflix Q1 earnings top estimates on blowout subscriber growth
- Nasdaq tumbles, Treasuries dip amid earnings, geopolitical crosscurrents
- Gold prices rally past $2,400 on reports of Israel strikes on Iran
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- Jabil falls after placing CEO on paid leave amid internal investigation
- Frontier Communications (FYBR) says third party had gained unauthorized access to portions of its information technology environment
- Ibotta (IBTA) Prices 6.56M Share IPO at $88/sh
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
Mylan's (MYL) EpiPen Settlement is Credit-Negative Development - Moody's
October 10, 2016 3:26 PM EDTMoody's Investors Service commented that Mylan's (Nasdaq: MYL) settlement with the US Department of Justice and other government agencies to resolve EpiPen's reimbursement classification with the Centers for Medicaid and Medicare Services is a credit negative development. There are no... More
Mylan's (MYL) EpiPen Settlement with DOJ Removes Key Risk Overhang - Fitch
October 10, 2016 2:21 PM EDTMylan's (Nasdaq: MYL) $465 million settlement of claims it had misclassified its EpiPen injector allays the otherwise significant risk of rebate recoup payments to Medicaid agencies related to the recent EpiPen scrutiny, according to Fitch Ratings. The firm remains subject to other government-related investigations, however.
Mylan announced last week a settlement with the federal government to "resolve questions that have been raised about the classification of EpiPen ... for purposes of the Medicaid Drug Rebate Program," according to a Mylan statement. Mylan had been accused of misclassifying EpiPen as a non-innovator multiple-source (or... More
Mylan (MYL): Don't Get Too Excited - RBC
October 10, 2016 7:24 AM EDTRBC Capital analyst, Randall Stanicky, reiterated his Sector Perform rating on shares of Mylan (NASDAQ: MYL) as the DOJ Epipen settlement removes the immediate overhang but notes that questions will linger on the P&L outlook. On Friday after the close MYL announced a... More
Mylan to pay $465 million over EpiPen Medicaid rebate dispute
October 7, 2016 5:04 PM EDTBy Deena Beasley
(Reuters) - Mylan NV (NASDAQ: MYL) on Friday said it will pay $465 million to settle questions of whether it underpaid U.S. government healthcare programs by misclassifying its EpiPen emergency allergy treatment, which has come under intense scrutiny after a series of drastic price increases.
Mylan has been lambasted by consumers and lawmakers for raising prices on the lifesaving EpiPen sixfold to over $600 for a package of two in less than a decade, making the devices unaffordable for a growing number of families.
Lawmakers were trying to... More